Pluristem begins preclinical study of PLX-1 for engraftment during bone marrow transplantation

By Lisa Kerner

Erie, Pa., April 24 - Pluristem Life Systems, Inc. has started an animal model study of its stem cell therapy product known as PLX-1, which is intended to improve engraftment during bone marrow transplant procedures that use umbilical cord blood (UCB).

Preliminary results of the PLX-1 study are expected during the second quarter of 2006.

"A major reason for the failure of many UCB transplants is the low engraftment rate of the transplanted hematopoietic stem cells," research and development director Ora Burger said in a company news release.

PLX-1 consists of adjuvant engineered mesenchymal stem cells that can be co-transplanted along with the hematopoietic stem cells. Because mesenchymal stem cells do not elicit an immunological response in the recipient, it eliminates the need for tissue matching, the company said.

Pluristem is a cell therapy company located in Haifa, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.